Related Experiment Video
Updated: Mar 26, 2026
11:36
Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
22.7K
[EXPERIENCE IN TREATING HELMINTHISM WITH MICRONIZED ALBENDAZOLE (GELMODOL)]
Meditsinskaia Parazitologiia I Parazitarnye Bolezni
|February 2, 2016
Summary
Micronized albendazole (Gelmodol-BM) effectively treated various helminth infections in 87 patients. The drug demonstrated high efficacy and good tolerability, comparable to other albendazole formulations.
Area of Science:
- Medical Parasitology
- Tropical Diseases
- Pharmacology
Context:
- Study conducted at the Department of Medical Parasitology and Tropical Diseases, I.M. Sechenov First Moscow State Medical University.
- Treatment involved 87 patients diagnosed with various helminthic infections between 2013-2014.
Purpose:
- To evaluate the efficacy and tolerability of micronized albendazole (Gelmodol-BM) in treating helminthiasis.
- To compare the effectiveness of Gelmodol-BM with other albendazole formulations.
Summary:
- Micronized albendazole was administered to patients with echinococcosis, alveococcosis, ascariasis, toxocariasis, enterobiasis, and larva migrans using standard dosages.
- The treatment demonstrated high efficacy and good tolerability across the diverse patient cohort.
- Results indicate Gelmodol-BM is a competitive and effective option for managing multiple helminthic diseases.
Impact:
- Provides evidence for the successful clinical application of micronized albendazole in treating a range of parasitic infections.
- Highlights Gelmodol-BM as a viable and effective alternative to existing albendazole medications.
- Contributes to the understanding of albendazole's therapeutic potential in medical parasitology.
More Related Videos
10:57Determining Soil-transmitted Helminth Infection Status and Physical Fitness of School-aged Children
Published on: August 22, 2012
24.7K
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
12.1K
Related Concept Videos
01:15Anthelminthic Agents
40
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
40
01:28Fungal Phylum Microsporidia
696
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
696
01:17Drugs for Treatment of Diarrhea-Predominant IBS
855
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
855
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
2.0K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.0K
01:21Drugs for Treatment of Constipation-Predominant IBS
1.2K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.2K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
608
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
608